Introduction to
FFPE Blocks with FoundationOne -Equivalent Genomic Profiling
Buy FFPE Blocks With FoundationOne Equivalent Profiling
FFPE blocks with FoundationOne-equivalent profiling are tumour specimens accompanied by broad genomic results intended to offer a scope comparable to established comprehensive genomic profiling approaches. Because “equivalent” does not mean identical, researchers should avoid assuming that another assay covers the same genes, alteration classes, analytical sensitivity or genomic signatures as a specific Foundation Medicine test. The supplier should identify the actual platform, panel version, genes evaluated and validation status.
Available findings may include substitutions, insertions, deletions, copy-number changes, gene rearrangements and selected genomic signatures. The FFPE tissue can support orthogonal confirmation, IHC, FISH, PCR, spatial analysis or repeat sequencing. Pathology quality control should establish tumour diagnosis, tumour content, necrosis and available material. Researchers should also verify that profiling was performed on the supplied block or clearly documented matched tissue. Transparent assay information is essential when purchasing these samples for oncology research, biomarker validation or molecular cohort development.
FFPE Tumor Blocks With Comprehensive Genomic Profiling Data
FFPE tumour blocks with comprehensive genomic profiling data provide researchers with physical cancer tissue linked to broad molecular findings. Depending on the assay, profiling may identify mutations, insertions, deletions, amplifications, losses, rearrangements and genomic signatures such as microsatellite instability or tumour mutational burden. Researchers can select blocks according to disease indication, histological subtype or molecular eligibility and use the remaining tissue for further laboratory analyses. The profiling report should specify the platform, panel content, analytical performance and interpretation of each reported alteration.
Optimized for DNA Sequencing
NGS-Ready FFPE Tissue Blocks
Reliable RNA Profiling Samples
Source FoundationOne Equivalent Profiled FFPE Samples
FoundationOne-equivalent profiled FFPE samples can be sourced using specific genomic, pathological and clinical criteria. Researchers should describe the required cancer type, histology, tumour site, stage, tissue quantity and molecular alterations. They should also define what constitutes acceptable “equivalent profiling,” including minimum panel size, covered genes, alteration classes, sequencing depth and required genomic signatures. The actual assay manufacturer and test version should always be disclosed.
Clinically Annotated Tissue Samples
FFPE blocks supplied with relevant clinical details for reliable genomic research.
Comprehensive Pathology Data Included
Each sample includes diagnosis, grade, stage, tumor content, and pathology information.
Optimized for Genomic Analysis
Samples are suitable for DNA, RNA, NGS, mutation analysis, and molecular profiling.
Reliable Samples for NGS
Quality-controlled FFPE blocks support accurate sequencing and reproducible genomic results.
Clinically Annotated FFPE Blocks With CGP Results
Clinically annotated FFPE blocks with comprehensive genomic profiling results combine physical tumour tissue, molecular findings and relevant patient information. Available annotations may include age, sex, diagnosis, histological subtype, stage, grade, specimen site, treatment history, response, progression and follow-up. Researchers should evaluate the completeness of these fields before cohort selection, especially when treatment outcomes are important. The CGP report should identify the assay, panel version, genes examined, alteration types assessed and quality-control findings.
Researchers should confirm that the supplied block corresponds to the tested tissue and consider possible heterogeneity when profiling was performed on a separate specimen. A recent pathology review can establish tumour content, necrosis and remaining material. All clinical and genomic information must be appropriately de-identified and covered by relevant consent and ethical permissions. These integrated specimens can support retrospective oncology studies, biomarker discovery, treatment-response research and multimodal AI development.
FFPE Blocks With FoundationOne Equivalent Data for Research
FFPE blocks with FoundationOne-equivalent data can support studies requiring broad molecular characterization without limiting procurement to one commercial testing provider. The actual profiling method should provide sufficient coverage of the genes and alteration types relevant to the project, but it should not be described as identical to FoundationOne unless equivalence has been formally demonstrated. Researchers should review the assay’s gene list, reportable variants, limits of detection, sequencing depth and approach to genomic signatures. The corresponding FFPE block may be used for IHC, FISH, PCR, repeat NGS or spatial biology investigations.
Pathology review should confirm diagnosis, tumour content and tissue sufficiency. Molecular results may also be used to select positive and negative cases for assay-development programmes. Negative cases require adequate coverage of the relevant gene and alteration class. Clear assay disclosure, traceable specimen matching and appropriate ethical documentation help make these blocks suitable for dependable oncology and biomarker research.
Order Molecularly Characterized FFPE Tumor Blocks With CGP Data
Molecularly characterized FFPE tumour blocks with CGP data can be ordered according to customised research specifications. The request should define tumour indication, histological subtype, primary or metastatic status, stage, minimum tumour content and required tissue quantity. Molecular requirements may include actionable mutations, gene fusions, copy-number changes, resistance alterations, microsatellite instability or specified tumour mutational burden ranges. Researchers should identify acceptable profiling platforms and the minimum required gene and alteration coverage. Supporting documents may include an H&E image, pathology summary, de-identified CGP report and available clinical annotations. A pathologist should confirm that sufficient representative tumour remains for downstream testing. Selected findings may be orthogonally verified where necessary. All samples should be transferred under appropriate consent, ethics, privacy and material-transfer requirements. A structured ordering process helps biotechnology, pharmaceutical and academic teams create focused, quality-controlled CGP cohorts for research and assay development.
General Questions
Frequent Asked Questions!!
FFPE blocks for genomics are formalin-fixed, paraffin-embedded tissue samples used for DNA, RNA, and biomarker analysis. They are widely used in cancer genomics, molecular pathology, translational research, and retrospective studies.
FFPE tissue blocks are valuable because they preserve tissue architecture and molecular material for long-term storage. Researchers can use them for sequencing, mutation analysis, biomarker discovery, and validation studies.
Yes. DNA can be extracted from FFPE blocks using validated extraction kits and optimized laboratory protocols. DNA quality depends on fixation time, block age, tissue type, tumor content, and storage conditions.
Yes. RNA can be extracted from FFPE tissue, although it is often fragmented because of formalin fixation. Specialized FFPE RNA extraction methods can provide material suitable for targeted RNA sequencing, gene expression studies, and fusion analysis.
Yes. High-quality FFPE blocks are commonly used for next-generation sequencing, including targeted sequencing panels, whole-exome sequencing, RNA sequencing, and selected whole-genome applications.
Tumor content requirements depend on the study design and testing method. Many molecular and NGS studies require at least 20% tumor content, while some projects may require 30%, 50%, or higher tumor percentage. Pathologist review can be performed to confirm tumor content before shipment
FFPE blocks can support mutation testing, copy number analysis, gene fusion detection, microsatellite instability testing, tumor mutational burden analysis, methylation studies, and targeted DNA or RNA sequencing.
Yes. FFPE cancer tissue blocks are extensively used to study genomic alterations in lung, breast, colorectal, prostate, ovarian, pancreatic, liver, kidney, and other tumor types.
Researchers can purchase FFPE blocks from qualified biospecimen suppliers, biobanks, pathology laboratories, hospitals, and research networks that provide ethically sourced and clinically annotated human tissue samples.
Researchers should confirm diagnosis, tissue type, tumor percentage, necrosis percentage, fixation details, block age, specimen size, available clinical data, pathology review, consent status, and intended research-use permissions.
Yes. Clinically annotated FFPE blocks may include donor age, sex, diagnosis, grade, stage, TNM classification, treatment history, pathology report, mutation status, and clinical outcome data.